Novozymes and Chr. Hansen Combine to Form Novonesis

Kerry Group to Acquire Lactase Enzyme Business from Chr. Hansen and Novozymes

December 14, 2023

Food & Beverage

Kerry Group PLC has agreed to acquire part of the global lactase enzyme business carved out from Chr. Hansen Holding A/S and Novozymes A/S for a total consideration of €150 million (subject to closing adjustments). The deal includes certain trade and assets of Chr. Hansen's global lactase business and 100% of Nuocheng Trillion Food (Tianjin) Co., Ltd.; the lactase business generated about €40 million in revenue in 2022 and the transaction is expected to close in the first half of 2024 subject to European Commission approval.

Chr. Hansen Acquires UAS Laboratories LLC

June 9, 2020

Biotechnology

Chr. Hansen Holding A/S has agreed to acquire 100% of UAS Laboratories LLC from Lakeview Equity Partners, the UAS management team and other shareholders for USD 530 million (net of tax assets). The acquisition (UAS Labs: ~230 employees, ~USD 85m revenue and >USD 30m EBITDA in 2020) strengthens Chr. Hansen’s microbial platform and Human Health business by adding probiotic strains, two GMP production facilities in Wisconsin, and increased fermentation and downstream processing capacity.

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.

Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

February 1, 2024

Biotechnology

Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.

BioCina and NovaCina Merge to Create Integrated Global CDMO

January 13, 2025

Pharmaceuticals

BioCina and NovaCina announced a strategic merger that will combine BioCina's process development and manufacturing capabilities in Adelaide with NovaCina's sterile fill-finish facility in Perth. The combined company will retain the BioCina name and provide an end-to-end CDMO offering for small molecules and biopharmaceuticals, backed by parent Bridgewest Group.

BioMarin Acquires Inozyme Pharma

May 16, 2025

Biotechnology

BioMarin Pharmaceutical Inc. completed its acquisition of Inozyme Pharma, Inc. in an all-cash transaction valued at approximately $270 million ($4.00 per share). The deal adds Inozyme's late-stage enzyme replacement therapy INZ-701 for ENPP1 Deficiency to BioMarin's enzyme-therapy portfolio and is expected to accelerate development toward potential regulatory approval.